Among these, 26 genes (CCNA1, CCNA2, CCNB2, CCND1, CCND2, CCND3, CDKN2B, COL1A1, EGFR, EGR1, ELK1, ETS1, ETS2, FOS, GRB2, JUN, MAPK13, MAPK14, MAP2K7, MAP3K1, MAP3K3, MAP4K1, MEF2C, MKNK1, NFATC4, and SFN) exhibited reduced expression, while five genes (CDK6, CHUK, HSPA5, MAPK8IP2, and MAPK9) showed increased expression in FTC compared to PTC samples (Figure 1d) (p ≤ 0.05). The gene discussed is MAPK9; the disease is thyroid cancer, nonmedullary, 2.